^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement |
|---|---|
| Cancer: | Lymphoma |
| Drug: | SGN-CD19B (DNA replication inhibitor, CD19-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies
Excerpt:
Lymphoma cell lines with MYC, BCL2, and/or BCL6 rearrangements indicated by an asterisk in Figure 1, were among the cells that showed high sensitivity to SGN-CD19B.
DOI:
https://doi.org/10.1182/blood-2017-04-779389
